SMARCD2

Across TCGA pan-cancer cohorts, SMARCD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMARCD2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SMARCD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMARCD2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LUAD, READ, and BLCA are the cancer types where SMARCD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.147	0.679	.001	18	view →
READ	DFS	Median	All	0.276	0.702	.022	9	view →
BLCA	DFS	Median	All	1.000	0.328	.036	4	view →
UCEC	DFS	Median	All	0.959	0.621	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMARCD2–LUAD (OS)

Open the LUAD breakdown →